Tirzepatide (CAS No.: 2023788-19-2) - Dual GIP/GLP-1 Receptor Agonist rau Hom 2 Diabetes & Obesity
Raws li tus kws tshaj lij ntawm cov kws kho mob - qib peptide cov khoom xyaw tshuaj nquag (APIs), peb muab siab -purity Tirzepatide uas nruj me ntsis ua raws li cov qauv tshuaj tshuaj thoob ntiaj teb (USP, EP, BP). Thawj -hauv-chav kawm dual qabzib-nyob ntawm insulinotropic polypeptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1) receptor agonist, nws muaj kev tswj glycemic zoo tshaj plaws thiab txo qhov hnyav los ntawm kev tsom mus rau ob qho tseem ceeb incretin pathways-ua rau tus neeg mob ntshav qab zib hom 2. (T2DM) thiab tswj kev rog rog.
Product Basic Information
| Yam khoom | Paub meej |
|---|---|
| Khoom npe | Tirzepatide |
| CAS Nr. | 2023788-19-2 |
| Molecular Formula | C₂₄₉H₃₇₅N₆₅O₇₃S₆ |
| Molecular Luj | 5917.65 |
| Qhov tshwm sim | Dawb rau tawm -dawb lyophilized hmoov; Tsis hnov tsw |
| Specification | Pharmaceutical qib; Purity Ntau dua lossis sib npaug li 99.0% (HPLC); Poob ntawm ziab Tsawg dua lossis sib npaug li 3.0%; Residue ntawm ignition Tsawg dua los yog sib npaug rau 0.1%; Cov hlau hnyav (Pb, Hg, Cd) Tsawg dua lossis sib npaug li 10ppm; Cov kuab tshuaj residue (acetonitrile, dej) ua raws li ICH Q3C txwv; Endotoxin Tsawg dua lossis sib npaug rau 0.25 EU / mg |
Product Core Functions & Applications
Tirzepatide CAS No # 2023788-19-2 exerts nws cov tshuaj pharmacological los ntawmIb txhij ua kom GIP thiab GLP-1 receptors-ib lub tswv yim tshwj xeeb uas sib koom ua ke tswj cov piam thaj metabolism thiab lub cev hnyav. GIP txhim kho insulin secretion thiab txo kev noj zaub mov, thaum GLP-1 inhibits glucagon, ua rau lub plab zom mov, thiab txo qis qab los noj mov. Nws qhov txiaj ntsig tseem ceeb yog antev ib nrab -lub neej (~ 5 hnub), tso cai ib zaug - kev tswj hwm txhua lub lim tiam nrog kev ua tau zoo. Nws tsuas yog siv rau hauv tib neeg cov tshuaj formulations:
1. Kev kho mob ntshav qab zib hom 2 (T2DM).
Monotherapy: Rau cov neeg mob uas muaj T2DM tswj tsis tau zoo los ntawm kev hloov pauv txoj kev ua neej, nws txo glycated hemoglobin (HbA1c) los ntawm 1.5-2.0% thiab ceev cov ntshav qabzib los ntawm 30-50 mg / dL.
Kev Kho Mob Ua Ke: Siv nrog metformin, SGLT2 inhibitors, lossis insulin kom ua tiav kev tswj glycemic zoo dua piv rau ib leeg incretin agonists- nrog HbA1c txo mus txog 2.5% hauv kev kho triple.
Cov txiaj ntsig ntawm Cardiometabolic: Txhim kho ntau yam kab mob plawv, suav nrog ntshav siab, triglycerides, thiab lub duav ncig, ntxiv rau kev tswj glycemic.
2. Kev Tswj Kev Noj Qab Haus Huv Ntev
Qhia rau cov neeg laus uas muaj qhov hnyav ntawm lub cev (BMI) Ntau dua lossis sib npaug li 30 kg / m² (obesity) lossis BMI Ntau dua lossis sib npaug li 27 kg / m² (hnyav) nrog tsawg kawg ib qhov hnyav -txog comorbidity (xws li, kub siab, dyslipidemia, T2DM).
Ua kom poob ceeb thawj tseem ceeb (nruab nrab 15-20% ntawm qhov hnyav tshaj 72 lub lis piam)- zoo tshaj rau ib leeg GLP-1 agonists-los ntawm kev sib txuas GIP-kho kev siv hluav taws xob kho kom zoo dua nrog GLP-1-induced qab los noj mov.
Daim ntawv noj tshuaj
Cov tshuaj txhaj tshuaj: Pre- cov cwj mem puv (2.5 mg / 0.5 mL, 5 mg / 0.5 mL, 7.5 mg / 0.5 mL, 10 mg / 0.5 mL) rau kev txhaj tshuaj subcutaneous (lub plab, ncej puab, sab caj npab), muab tshuaj ib zaug ib lub lim tiam. Kev nce koob tshuaj (pib los ntawm 2.5 mg) txo qis kev mob plab hnyuv.
Quality & Safety Assurance
raws li qhov tshiab dual -action peptide API, yuav tsum muaj kev tswj xyuas nruj kom ntseeg tau tias muaj txiaj ntsig, ruaj khov, thiab kev nyab xeeb:
Raw Material Sourcing & Production
Precursor Xaiv: Siv siab -purity recombinant GIP/GLP-1 hybrid peptide precursors thiab kev hloov kho hluavtaws (xws li, lipidation rau ncua ib nrab-lub neej) los txhim kho receptor binding affinity thiab txo cov immunogenicity.
Kev tsim khoom: Ua nyob rau hauv GMP- ntawv pov thawj cleanrooms los ntawm advanced solid-theem peptide synthesis (SPPS) thiab post-translational lipid conjugation. Kev tswj nruj nruj ntawm kev sib txuas ua haujlwm, kev ua kom huv (ntau-pab HPLC), thiab lyophilization ua kom batch-rau-batch sib xws thiab ntev- lub sij hawm ruaj khov.
Comprehensive Testing Protocols
Txhua batch raug kuaj nruj kom ua tau raws li cov qauv tshuaj pharmacopoeia thoob ntiaj teb:
Purity & Lwm yam khoom: HPLC tsom xam (purity Ntau dua lossis sib npaug li 99.0%, ib qho impurity Tsawg dua lossis sib npaug li 0.5%, tag nrho impurities Tsawg dua lossis sib npaug li 1.0%).
Peptide Identity: Pom zoo los ntawm huab hwm coj spectrometry thiab amino acid sequence pov thawj.
Kev kuaj lub cev & tshuaj: Kev sib hloov kho qhov muag tshwj xeeb (+55℃rau +65℃, hauv 0.1M acetic acid), cov ntsiab lus noo noo (Karl Fischer txoj kev Tsawg dua lossis sib npaug li 3.0%), thiab pH (6.5-7.5 rau kev kho dua tshiab).
Kev ntsuam xyuas kev nyab xeeb: Kev kuaj xyuas cov hlau hnyav (ICP-MS), kuaj kab mob microbial (tag nrho cov aerobic microbial suav Tsawg dua lossis sib npaug li 100 CFU/g), kuaj tsis muaj menyuam (rau txhaj tshuaj - qib API), thiab kuaj endotoxin (tsawg dua lossis sib npaug rau 0.25 EU/mg).
Kev ceeb toom kev nyab xeeb
Cov teebmeem tshwm sim: Cov tshuaj tiv thaiv kab mob plab (xeev, raws plab, ntuav, cem quav)-zoo ib yam li GLP-1 agonists tab sis feem ntau me me mus rau nruab nrab, txhim kho nrog kev nce koob tshuaj.
Kev pheej hmoo loj:
Pancreatitis: Saib xyuas qhov mob plab mob hnyav heev; txiav tawm yog tias xav tau.
Thyroid C-Cell Tumor Risk: Contraindicated nyob rau hauv cov neeg mob uas muaj tus kheej / tsev neeg keeb kwm ntawm medullary thyroid carcinoma (MTC) los yog ntau yam endocrine neoplasia syndrome hom 2 (MEN 2).
Hypoglycemia: Kev pheej hmoo nce ntxiv nrog cov tshuaj insulin los yog sulfonylureas-txo cov tshuaj no los ntawm 20-50% thawj zaug.
Cov xwm txheej rau lub raum: Tej zaum yuav ua rau mob raum raug mob rau cov neeg mob lub cev qhuav dej (vim ntuav / raws plab); xyuas kom muaj dej txaus.
Contraindications: Hypersensitivity rau Tirzepatide los yog lwm yam excipients; MTC keeb kwm/tsev neeg keeb kwm; MEN 2.
Kev koom tes & kev sib cuag
Peb muab tshuaj -qib Tirzepatide CAS No#2023788-19-2 API rau cov tuam txhab ntawm ib zaug- cov tshuaj txhaj tshuaj txhua lub limtiam, nrog cov peev txheej tsim tau yooj yim (los ntawm cov qauv gram-theem R&D mus rau kilogram-theem txiav txim ntau). Yog tias koj yog ib lub tuam txhab kws tshuaj, R & D lub koom haum, lossis tus tsim qauv xav tau cov khoom no, thov hu rau peb rau:
Cov ntaub ntawv qhia txog kev ua raws cai ntawm pharmacopoeia (USP / EP monograph lees paub, daim ntawv pov thawj ntawm kev tshuaj xyuas).
Tus nqi quotes, bulk order discounts, thiab dawb R&D qauv thov.
Kev pab txhawb nqa (piv txwv li, formulation compatibility, reconstitution txheej txheem, peptide stability raws tu qauv).
Cov ntaub ntawv tiv tauj:
Email: sales@huarongpharma.com
Xov tooj/WhatsApp: +86 13751168070
Peb ua raws li cov hauv paus ntsiab lus ntawm "kev ua tau zoo ua ntej, ua raws li- taw qhia" thiab tos ntsoov yuav tsim kom muaj kev sib raug zoo ntev -, kev sib raug zoo nrog kev sib raug zoo nrog cov neeg koom tes thoob ntiaj teb!
Cov lus nug nquag nug (FAQs)
1. Cov kev mob tshwm sim ntawm Tirzepatide yog dab tsi?
Cov kev mob tshwm sim feem ntau yoggastrointestinal ntshawv siab, nrog rau xeev siab (35-50% ntawm cov neeg mob), raws plab (25-40%), ntuav (15-25%), cem quav (10-20%), thiab tsis qab los noj mov (30-45%). Cov no feem ntau yog nyob ntawm koob tshuaj, tshwm sim hauv thawj 4-6 lub lis piam, thiab feem ntau txhim kho nrog kev siv txuas ntxiv lossis qeeb dua koob tshuaj. Cov kev mob tshwm sim tsawg dua muaj xws li mob taub hau, qaug zog, thiab qhov chaw txhaj tshuaj me me (liab, khaus).
2. Tirzepatide ua haujlwm hauv lub cev li cas?
ua haujlwm los ntawm adual mechanismlos ntawm kev ua kom ob qho tib si GIP thiab GLP-1 receptors:
GIP Receptor Activation: Txhim kho insulin secretion (glucose{0}}dependent), txo glucagon tso tawm, thiab tuaj yeem ua rau kev siv zog ntau ntxiv - ua rau poob phaus.
GLP-1 Receptor Activation: Stimulates insulin secretion, suppresses glucagon, slows gastric emptying (txo postprandial qabzib spikes), thiab ua rau lub hlwb los suppress qab los noj mov.
Synergistic nyhuv: Kev sib xyaw ua ke ntawm GIP thiab GLP-1 kev ua tau ua rau muaj kev tswj hwm glycemic zoo dua thiab poob phaus ntau dua piv rau ib leeg incretin agonists.
Ntev Ib nrab-Lub Neej: Ib qho lipid saw txuas rau peptide khi rau albumin, ua kom qeeb kev tshem tawm thiab ua rau ib zaug - kev tswj hwm txhua lub lim tiam.
3. Puas muaj kev cuam tshuam tshuaj nrog Tirzepatide?
Yog lawm, muaj peev xwm ua kom qeeb plab hnyuv yuav cuam tshuam rau kev nqus ntawm lwm cov tshuaj hauv qhov ncauj. Cov kev sib tham tseem ceeb muaj xws li:
Qhov ncauj Hypoglycemics: Kev siv ua ke nrog cov tshuaj insulin lossis sulfonylureas ua rau muaj kev pheej hmoo ntawm hypoglycemia - txo cov koob tshuaj ntawm cov tshuaj no los ntawm 20-50% thaum xub thawj.
Cov tshuaj tiv thaiv qhov ncauj: Tej zaum yuav ncua kev nqus (nce siab concentration txo los ntawm ~ 25%); noj tsawg kawg 30 feeb ua ntej txhaj tshuaj Tirzepatide.
Tshuaj tua kab mob/Antifungals: Cov tshuaj uas yuav tsum tau nqus sai (piv txwv li, amoxicillin) yuav tsum tau noj 1 teev ua ntej lossis 2 teev tom qab nws.
Beta{0}}Blockers: Tej zaum yuav npog cov tsos mob hypoglycemia (piv txwv li, tachycardia); saib xyuas cov ntshav qabzib kom ze.
Glucocorticoids: Tej zaum yuav txo cov piam thaj - txo cov nyhuv; nce kev soj ntsuam thiab kho cov koob tshuaj yog tias xav tau.
Cim npe nrov: Tuam Tshoj Tirzepatide CAS Tsis # 2023788-19-2, Tuam Tshoj tirzepatide cas no # 2023788-19-2 manufacturers, lwm tus neeg
 - Fluoroquino9b7a2.png?size=118x0)
